Oral Ferrous Sulphate Improves Functional Capacity on Heart Failure Patients with Iron Deficiency Anemia

Accepted on 04 Aug 2022 Submitted on 20 Feb 2022

Introduction

Iron deficiency anemia (IDA) is one of the most common nutritional deficiencies in the world affecting approximately 15% global population and becoming a common co-morbidity in heart failure (HF) patients [1]. It is estimated that nearly 50% of HF patients have Iron deficiency regardless of anemia [2, 3]. Although the 2016 ESC heart failure guideline defined absolute ID as serum ferritin <100 ng/ml and functional ID as serum ferritin 100–299 ng/ml with transferrin saturation <20% [4]. The ID with or without anemia as HF comorbidity the independent predictor of mortality. Moreover, anemia in HF patient is also associated with lower functional capacity and quality of life [3, 4, 5, 6, 7].

Many studies have investigated that treating the anemia condition could give a positive effect for the outcome. One of the proven drugs of choice for treating this condition is intravenous (IV) iron supplement. This drug improved haemoglobin, ferritin, transferrin saturation and functional capacity [8, 9]. However, intravenous iron supplement is not readily available in low-to-middle income countries such as Indonesia. The main reason was the expensive IV iron regimen was not covered by National Health Insurance. Hence, there is a need to obtain a cheaper, more available alternative.

Oral iron supplementation such as ferrous sulphate tablets is readily available and is cheaper compared to IV iron supplement. (Table 1) However, recent opinion suggests that inflammation in HF patients can induce hepcidin level which inhibits iron absorption bioavailability [10, 11, 12, 13]. Confronting this opinion, Niehaus et al. showed that 130 mg of oral ferrous sulphate supplementation improved iron levels in HF patients [14]. Therefore, this study investigates the effectiveness of oral iron, especially ferrous sulphate on improving functional capacity in HFREF patients with IDA on Indonesia population. The importance of this study was finding the potency of a widely available oral iron regimen in Indonesia in the form of ferrous sulphate for heart failure with reduced ejection fraction.

Table 1

Comparison of Oral vs Intravenous Iron.

ORAL IRON INTRAVENOUS IRON PRICE INEXPENSIVE EXPENSIVE Administration Administered everywhere In-hospital administration Efficacy in Heart Failure Inconclusive efficacy High efficacy Adherence Low adherence due to high intake frequency High adherence due to single administration Availability in Developing Country Highly available Rarely available Methods

This study was designed as a single centre, randomized, double blind, placebo-controlled trial. It was approved by the institutional review board in National Cardiovascular Center Harapan Kita Hospital Universitas Indonesia (NCCHK-UI). This study was registered at Clinicaltrials.gov with registration number NCT 02998697. All of the co-authors were involved throughout the study conduct. All participants who eligible for the study gave their written consent.

This study was conducted in NCCHK-UI outpatient clinic from January until November 2016. The participants were selected based on following inclusion and exclusion criteria. Inclusion criteria were age 18–75 years old, HFREF <45% with NYHA functional class II–III who receives guideline directed medical therapy, haemoglobin (Hb) <13 g/dl for men and <12 g/dl for women, ferritin <100 ng/ml or between 100–300ng/ml with transferrin saturation <20%, eGFR >30 ml/min/1.73 m2, and willing to give written consent to join the study. Exclusion criteria were active bleeding, infection, malignancy, haematology disorder, peptic ulcer, intolerant to ferrous sulphate, received intravenous iron within past month, Implanted permanent pacemaker, intracardiac defibrillator, or cardiac resynchronization therapy, NT-pro BNP level >4000 pg/ml, liver disease with SGOT/SGPT >3x normal value, congenital heart disease, valvular heart disease, right heart failure due to pulmonary hypertension, underwent primary percutaneous intervention or coronary arterial bypass operation in the last three months, stroke or transient ischemic attack in the last three months.

Participants with HFREF and IDA who fulfilled inclusion and exclusion criteria were enrolled and randomized to receive either placebo or ferrous sulphate 200 mg three times a day (Kimia Farma, Indonesia) for 12 weeks. The subject allocation for each group was also randomized and concealed. Both of the participant and the investigator were blinded of the treatment. Before treatment initiation, the participant underwent baseline examination including clinical data, echocardiography, six-minute walk test (6MWT), and laboratory test such as iron profile, liver function, kidney function, and NT-pro BNP. Clinical follow up was performed every month in which we recorded clinical condition, pill counting, and side effect. Adverse events were observed and recorded within 12 weeks intervention period. After 12 weeks therapy, the participant underwent the same set of examination like the baseline for outcomes analysis.

The primary outcome was the differences of functional capacity measured by 6MWT after 12 weeks therapy of ferrous sulphate or placebo groups. Secondary outcomes including the differences of clinical outcomes, echocardiography parameters of left ventricular ejection fraction (LVEF), and laboratory results such as iron profile changes after 12 weeks intervention.

The type I error was set two-sided 0.05 with power of 80%. A minimal of 40 patients with HFREF and IDA would be randomized into 1:1 ratio and concealed to ferrous sulphate or placebo allocation for 12 weeks. A two-sided p value <0.05 was considered statistically significant. Baseline demographic, clinical, echocardiography, 6MWT, and laboratory examination including iron profile, liver function, kidney function, and NT-pro BNP were compared between placebo and ferrous sulphate group at baseline. Continuous and categorical data with normal distribution were displayed as mean ± standard error mean and percentage respectively. Abnormal continuous data distribution was displayed as median. Categorical data was displayed as percentage. Categorical data was analyzed using Chi square test. Numerical data was analyzed using independent t-tests with Welch’s correction for normal distribution or Mann Whitney test for abnormal distribution data. Analyses were performed using GraphPad prism version 8.3 (GraphPad Software. San Diego, CA 9218).

Results

We enrolled 172 HFREF patients from January until November 2016 (Figure 1). A total of 54 participants who fulfilled HFREF and IDA inclusion and exclusion criteria were randomized to receive ferrous sulphate or placebo group with 1:1 ratio. We observed three mortality events with 1 mortality on ferrous sulphate group and 2 mortality events on placebo group. One participant was loss to follow-up on ferrous sulphate group. Four participants from ferrous group discontinued their medication with 2 participants went to other hospital, 1 suffered from pneumonia infection, and 1 participant complained worsened dyspnoea. Five participants from placebo group discontinued their medication with 1 participant excluded due to pacemaker implantation, 3 participants went to other hospital, 1 participant complained worsened dyspnoea, and 1 participant complained worsened diarrhea. In the end, a total of 41 participants completed the study with 22 participants on ferrous sulphate and 19 participants on placebo.

A workflow diagram on getting the 19 placebo subjects and 22 ferrous subjects

Figure 1

Consort diagram flow of this study. HF: Heart failure, eGFR: estimated glomerular filtration rate, 6MWT: 6-minute walk test.

Baseline characteristics of those groups were presented in Table 2. Overall, we did not find significant baseline difference between both groups. The mean age was 58 ± 9 and 57 ± 10 years old for ferrous sulphate and placebo group respectively. Both groups have NYHA functional class II–III. The mean LVEF was 34 ± 9% and 35 + 11% for ferrous group and placebo respectively. Functional capacity for both groups were 300 ± 85 and 309 ± 75 meter for ferrous sulphate and placebo group respectively. Level of mean haemoglobin on ferrous group was 11.6 ± 1.8 g/dl while 11.3 ± 1 for g/dl for placebo. Serum ferritin level was preserved >100 ng/dl for both groups with 121 ± 108 ng/ml on ferrous sulphate group and 110 ± 72 ng/ml on placebo. Both groups received similar heart failure guideline directed medical therapy.

Table 2

Baseline characteristics.

VARIABLE GROUP/CATEGORY P VALUE FERROUS SULPHATE (N = 27) PLACEBO (N = 27) Gender Male 15 (68.2%) 11 (57.9%) 0.3 Female 7 (31.8%) 8 (42.1%) 0.3 Age (y.o) 58 ± 9 57 ± 10 0.7 BMI (kg/m2) 23.90 ± 3.62 22.87 ± 2.88 0.8 Hypertension 19 (86.4%) 16 (84.2%) 0.6 Diabetes 13 (59.1%) 11 (57.9%) 0.9 ADHF hospitalization 17 (77.3%) 16 (84.2%) 0.4 ACS hospitalization 11 (50%) 13 (68.4%) 0.3 Stroke 2 (9.1%) 3 (15.8%) 0.5 Gastrointestinal bleeding 2 (9.1%) 2 (10.5%) 0.9 Gastritis 4 (18.2%) 4 (21.1%) 0.8 History of CABG 4 (18.2%) 3 (15.8%) 0.8 History of PCI 10 (45.5%) 11 (57.9%) 0.4 Coronary Disease Normal Coronary 2 (9.1%) 2 (10.5%) 0.18 1 Vessel disease 3 (13.6%) 7 (36.8%) 2 Vessel disease 3 (13.6%) 1 (5.3%) 3 Vessel disease 11 (50%) 6 (31.6%) Not revascularize 3 (13.6%) 3 (15.8%) Atrial Fibrillation 4 (16.7%) 0 (0%) 0.09 Systolic BP (mmHg) 127 ± 22 118 ± 19 0.06 Diastolic BP (mmHg) 70 ± 13 70 ± 15 0.8 Peripheral pulse (x/min) 79 ± 15 82 ± 16 0.9 LVEF (%) 34 ± 9 35 ± 11 0.7 TAPSE (cm) 1.82 ± 0.48 1.80 ± 0.45 0.9 6MWT (m) 300 ± 85 309 ± 75 0.7 NYHA Functional Class 0.3 I 0 (0%) 0 (0%) II 11 (50.0%) 11 (57.9%) III 11 (50%) 8 (42.1%) IV 0 (0%) 0 (0%) Haemoglobin (g/dL) 11.6 ± 1.8 11.3 ± 1.0 0.6 Ferritin (ng/mL) 121 ± 108 110 ± 72 0.6 Transferin saturation (%) 15.6 ± 5 17 ± 7.6 0.4 eGFR (mL/min) 57 ± 30 51 ± 26 0.4 NT-pro BNP (pg/mL) 2810 ± 3116 3105 + 2354 0.7 Lactic acid (mmol/L) 1.4 ± 0.6 1.3 ± 0.6 0.4 SGOT (U/L) 18 ± 9 19 ± 6.6 0.6 SGPT (U/L) 18.6 ± 10.7 20 ± 13 0.6 eGFR 50.9 ± 26.2 57.4 ± 29.5 0.4 Haematocrit (%) 37.30 ± 5.41 33.58 ± 2.97 0.3 Relative reticulocyte (%) 1.3 ± 0.50 1 ± 0.43 0.2 Erythrocyte (106/µL) 4.4 ± 0.83 4.10 ± 0.57 0.6 Leukocyte (103/µL) 7.927 ± 2.2 7.938 ± 2.1 0.9 Platelet (103/µL) 294 ± 609 270 ± 736 0.2 RDW (%) 14.3 ± 1.8 15 ± 1.8 0.2 MCV (fL) 84 ± 6.2 83 ± 8.0 0.8 MCH (pg) 28 ± 2.2 28 ± 3.5 0.9 MCHC (g/dL) 33 ± 1.0 33 ± 1.4 0.5 Medication – Diuretic 21 (95.5%) 16 (84.2%) 0.2 – ACE-I/ARB 22 (100%) 19 (100%) 1 – Beta Blocker 18 (81.8%) 18 (94.7%) 0.2 – MRA 9 (40.9%) 6 (31.6%) 0.5 – Statin 20 (90.9%) 18 (94.7%) 0.6 – Antiplatelet 20 (90.9%) 15 (78.9%) 0.3 – Anticoagulant 2 (9.1%) 4 (21.1%) 0.3 – Digitalis 2 (9.1%) 2 (10.5%) 0.9

No significant baseline differences between groups. Abbreviation: BMI = body mass index, ADHF = acute decompensated heart failure, ACS = acute coronary syndrome, eGFR = estimated glomerular filtration rate, RDW = red cell distribution width, MCV = mean corpuscular volume, MCH = mean corpuscular haemoglobin, MCHC = mean corpuscular haemoglobin concentration, ACE-I = Angiotensin II converting enzyme inhibitor, ARB=Angiotensin II receptor blocker.

We found a significant 6MWT functional capacity improvement in ferrous sulphate compared to placebo group after 12 weeks therapy (46.23 ± 35 m vs –13.7 ± 46 m, p < 0.001, CI –86.8 to –33.2, Figure 2A). Following 12 weeks intervention, we discovered a significant increase of haemoglobin levels in ferrous sulphate compared with placebo group (12.7 ± 1.8 g/dl vs 11.3 ± 1 g/dl, p = 0.004, CI –2.3 to –0.4, Figure 2B). We also observed a significantly higher ferritin levels in ferrous sulphate compared with placebo group (207.3 ± 104 ng/ml vs 111.7 ± 81.4 ng/ml, p = 0.001, CI –160 to –41.87, Figure 2C). Lastly, there was also a substantial TSAT increased in Ferrous group compared to placebo (29.5 ± 10.4% vs 20 ± 10.6%, p = 0.008, CI –16.3 to –2.6, Figure 2D). We presented the baseline and after 12-weeks follow up of the primary output in Table 3.

Four diagrams showing that ferrous sulphate was significantly better than placebo on 6MWT FC, Haemolglobin, Ferritin, & Transferrin saturation after 12 weeks intervention

Figure 2

6MWT functional capacity, haemoglobin, and iron profiles after 12 weeks intervention. A. Significant functional capacity improvement in FS group compare to placebo. B–D. Ferrous sulphate significantly increase haemoglobin, ferritin, and transferrin saturation, and levels respectively compared to placebo.

Table 3

Primary Outcome Baseline and 12-Weeks Follow Up.

VARIABLE GROUP/CATEGORY FERROUS SULPHATE (N = 27) PLACEBO (N = 27) BASELINE 12-FU BASELINE 12-FU 6MWT Functional Capacity 300 ± 85 349 ± 86 309 ± 75 305 ± 85 Haemoglobin 11.6 ± 1.8 12.6 ± 1.8 11.3 ± 1.0 11.2 ± 1 Ferritin 121 ± 108 207 ± 106 110 ± 72 112 ± 83 Transferrin Saturation 15.6 ± 5 28 ± 10 17 ± 7.6 20 ± 11 NT-pro BNP 2810 ± 3116 1645 ± 1289 3105 ± 2354 1262 (128 – 7424)a LVEF 34 ± 9 37 ± 10 35 ± 11 34 ± 12

a = presented in median (min – max) due to abnormal data. Abbreviation: 6MWT = 6-minute walk test, NT-pro BNP = N Terminal pro Brain Natriuretic Peptides, LVEF = left ventricular ejection fraction.

We observed a significant NYHA functional class improvement after 12 weeks intervention in ferrous sulphate group compared with placebo group after with p = 0.01 (Table 4). There was no significant difference of adverse event between both groups during 12 weeks monitoring. We reported 1 HF rehospitalization on ferrous sulphate and 2 HF rehospitalization on placebo group. We found 1 mortality event on ferrous sulphate group and 2 mortality events on placebo group. Two severe gastrointestinal side effect on each group were discovered. In addition, we also recorded 5 minor gastrointestinal side effect on ferrous sulphate group and 7 minor gastrointestinal side effect on placebo group during 12 weeks monitoring. These adverse and side effect findings are summarized in Table 5.

Table 4

NYHA functional class after 12 weeks intervention.

NYHA FUNCTIONAL CLASS FERROUS SULPHATE PLACEBO CHI SQUARE P VALUE I 2 (9%) 0 0.001 II 18 (82%) 2 (10%) III 2 (9%) 17 (90%) Total 22 19

Lower proportion of NYHA class III in ferrous sulphate compared to placebo group. Abbreviation: NYHA = New York Heart Association.

Table 5

Adverse event and gastrointestinal side effects.

EVENTS FERROUS SULPHATE (N) PLACEBO (N) P VALUE HF rehospitalization 1/27 2/27 0.4 Death 1/27 2/27 0.4 Severe gastrointestinal side effects 2/27 2/27 0.4 Minor gastrointestinal side effects 5/27 7/27 0.1 Total Events 9/27 13/27

Abbreviation: HF= heart failure.

We did not observe significant NT-pro BNP differences between both groups after 12 weeks intervention (ferrous sulphate 1625 ± 1233 pg/ml vs placebo 2055 ± 1931 pg/ml, p = 0.3, CI –478 to 1682, Figure 3A). We also did not find significant LVEF differences between both groups after 12 weeks intervention (ferrous sulphate 37 + 10.3% vs placebo 34.8 + 12.2%, p = 0.5, CI –9.8 to 5.4, Figure 3B).

Two diagrams showing that ferrous sulphate was not significantly better than placebo on NT-pro BNP level & LVEF after 12 weeks intervention

Figure 3

NT-pro BNP and LVEF after 12 weeks intervention. A–B. No significant NT-pro BNP and LVEF respectively between both groups after 12 weeks intervention.

Discussion

We conducted a single centre, randomized double-blind, placebo-control trial to investigate the effect of oral iron supplementation in HFREF patients with IDA. We found significant improvement of functional capacity from 6MWT and NYHA functional class after 12 weeks ferrous sulphate treatment compared to declining functional capacity in placebo group. In addition, ferrous sulphate treatment for 12 weeks was able to increase haemoglobin, ferritin and TSAT levels. Overall, ferrous sulphate is well tolerated without any significant adverse event differences between both groups.

Our study demonstrated the benefit of ferrous sulphate 200 mg daily three times a day for 12 weeks on improving functional capacity and restoring iron profiles. We observed 0.9 g/dl Hb, 69% ferritin, 88% TSAT increment which comparable to IV iron supplementation studies such as FAIR-HF and CONFIRM-HF [8, 15]. In accordance, our 6MWT functional capacity improvement was also comparable with those studies supporting the benefit of iron profile restoration in HF patients with anemia due to ID. The possible explanation on why the oral iron supplementation on our study could improve the functional capacity was because oral ferrous sulphate can be absorbed better the other oral iron regimen. Despite improvement of functional capacity in our study, we could not identify significant amelioration on NT-pro BNP and LVEF. We think that the time span in this study was too short to induce substantial recovery in myocardial function.

Iron profiles and haemoglobin restoration in our study suggest the occurrence of iron absorption through gastrointestinal tract. Previous studies assumed that oral iron supplementation was not efficient in HF patient with IDA due to high hepcidin level [16, 17, 18, 19]. However, the role of hepcidin in HF with IDA is still debatable as there are conflicting results. Elevated hepcidin levels were observed in HF patients with mild symptom NYHA functional class I–II [19]. However, the elevation of hepcidin in this study was not correlated with IL-6 which was considered as inflammatory cytokines that increased hepcidin level and reduced GI iron absorption. Hence, high ferritin on this study suggests that hepcidin elevation was secondary due to high ferritin. Furthermore, low hepcidin level was exhibited in advanced HF [19, 20, 21]. Previous studies showed that dilutional anemia and elevated erythropoietin in more severe HF might decrease hepcidin levels and nullify the effect of inflammation on hepcidin [20, 21]. Our HF population displayed functional IDA with moderate NYHA functional class II–III and elevated NT-pro BNP.

Contradictive oral iron supplementation in HFREF with IDA result was reported by IRONOUT HF study [22]. They observed no significant ferritin, TSAT, and 6MWT functional capacity changes after 16 weeks iron polysaccharide supplementation 150 mg twice daily. These conflicting results might be explained by the differences of oral iron types. Iron polysaccharide was known to be more tolerable compared to ferrous sulphate [23]. However, our study did not show significant adverse effect differences between ferrous sulphate and placebo group. Recent studies demonstrated higher iron restoration on ferrous group compared to iron polysaccharide group without significant side effect differences [23, 24, 25].

As mentioned earlier, the conflicting results of this study and the previous ones might be explained by the differences in oral iron types. In this study, the oral ferrous sulfate was indicated to have better efficacy than ferrous polysaccharide. In the BESTIRON study, a randomized, double-blind single-center trial designed to compare the effectiveness of an iron polysaccharide complex vs. ferrous sulfate for the treatment of nutritional ID anemia in infants and young children, the ferrous sulphate resulted in a more significant increase in hemoglobin concentration at 12 weeks [26]. Furthermore, In IRON-HF study, both ferrous sulphate or IV iron sucrose supplementation for five weeks in HFREF patients with IDA was significantly able to increase ferritin and TSAT levels [9]. Although, no functional capacity improvement was observed on five weeks ferrous sulphate group in IRON-HF study. Our results suggest that at least 12 weeks ferrous sulphate treatment was needed to improve functional capacity in HF patients with IDA. Moreover, ferrous sulphate is cheaper and widely available in developing country such as Indonesia. Therefore, we think that ferrous sulphate can be used as an alternative to iron IV for restoring iron profile and improving functional capacity in HFREF patients with IDA.

Limitation

Due to limited resources, we did not evaluate hepcidin which would provide excellent mechanistic insight on iron metabolism in our populations. Previous studies showed that higher hepcidin levels which often found in HF patients inhibited oral iron absorption thus limiting its bioavailability. Nevertheless, we found significant restoration of iron profiles which suggest oral iron GI absorption occurrence.

Conclusions

Oral ferrous sulphate for 12 weeks significantly improved functional capacity and NYHA functional class in HFREF patients with IDA. Furthermore, oral ferrous sulphate for 12 weeks also restored haemoglobin and iron profiles. Therefore, oral ferrous sulphate remains a feasible alternative therapeutic option for HFREF patients with IDA in developing countries especially in Indonesia.

Take Home Message

Oral ferrous sulphate has a huge potential as adjunctive therapy for heart failure patients with iron deficiency anemia, especially in developing countries like Indonesia. Further investigation in multiple centers with a bigger sample size will be very beneficial to gain a better conclusion regarding the topic.

Data Accessibility Statement

The data will be available for the readers if requested for further iron supplementation in heart failure research.

Abbreviations

6MWT: 6-minute Walk Test

CI: Confidence Interval

eGFR: Estimated Glomerulus Filtration Rate

FS: Ferrous Sulphate

GI: Gastrointestinal

Hb: Hemoglobin

HF: Heart Failure

HFREF: Heart Failure with Reduced Ejection Fraction

IDA: Iron Deficiency Anemia

IV: Intravenous

LVEF: Left Ventricular Ejection Fraction

NCCHK-UI: National Cardiovascular Center Harapan Kita Hospital Universitas Indonesia

NT-pro BNP: N-Terminal Pro Brain Natriuretic Peptide

NYHA: New York Heart Association

SGOT: Serum Glutamic Oxaloacetic Transaminase

SGPT: Serum Glutamic Pyruvic Transaminase

TSAT: Transferrin Saturation

Ethics and Consent

Accepted by Institutional Review Board of the National Cardiovascular Center Harapan Kita (Reference number: LB.02.01/VII/077/KEP.033EV).

Funding Information

This study was supported by Universitas Indonesia grant for International Publication. Kimia Farma company provided oral ferrous sulphate without supporting any funding and any role in the rationale, study design, conduct, analysis, or reporting.

Competing Interests

The authors have no competing interests to declare.

Author Contributions

LDS: conceptualization, methodology, investigation, formal analysis, and writing-original draft. SBR: conceptualization, methodology, and supervision. FDS: validation and supervision. HA: Investigation and data curation. RS: Investigation and data curation NH: validation and supervision. RS: validation and supervision. BBS: conceptualization, methodology, validation, supervision and funding acquisition. HSM: conceptualization, methodology, validation, supervision, formal analysis, visualization, writing-review & editing. YLP: writing-review and editing.

Publisher’s Note

Dr Nani Hersunarti was a submitting author on this paper, and was involved in the accumulation and analysis of data in a senior capacity. Unfortunately, she passed away after submission was not able to participate actively during the revisions, or sign off the final version.

References

Pasricha S. Anemia: a comprehensive global estimate. Blood. 2014; 123(5): 611–612. DOI: https://doi.org/10.1182/blood-2013-12-543405

Tang Y, Katz S. The prevalence of anemia in chronic heart failure and its impact on the clinical outcomes. Heart Failure Reviews. 2008; 13(4): 387–392. DOI: https://doi.org/10.1007/s10741-008-9089-7

Klip I, Comin-Colet J, Voors A, et al. Iron deficiency in chronic heart failure: An international pooled analysis. American Heart Journal. 2013; 165(4): 575–582.e3. DOI: https://doi.org/10.1016/j.ahj.2013.01.017

Ponikowski P, Voors A, Anker S, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. European Journal of Heart Failure. 2016; 18(8): 891–975. DOI: https://doi.org/10.1002/ejhf.592

Jankowska E, Rozentryt P, Witkowska A, et al. Iron deficiency: an ominous sign in patients with systolic chronic heart failure. European Heart Journal. 2010; 31(15): 1872–1880. DOI: https://doi.org/10.1093/eurheartj/ehq158

Aung N, Ling H, Cheng A, et al. Expansion of the red cell distribution width and evolving iron deficiency as predictors of poor outcome in chronic heart failure. International Journal of Cardiology. 2013; 168(3): 1997–2002. DOI: https://doi.org/10.1016/j.ijcard.2012.12.091

Okonko D, Mandal A, Missouris C, Poole-Wilson P. Disordered Iron Homeostasis in Chronic Heart Failure. Journal of the American College of Cardiology. 2011; 58(12): 1241–1251. DOI: https://doi.org/10.1016/j.jacc.2011.04.040

Anker S, Comin Colet J, Filippatos G, et al. Ferric Carboxymaltose in Patients with Heart Failure and Iron Deficiency. New England Journal of Medicine. 2009; 361(25): 2436–2448. DOI: https://doi.org/10.1056/NEJMoa0908355

Beck-da-Silva L, Piardi D, Soder S, et al. IRON-HF study: A randomized trial to assess the effects of iron in heart failure patients with anemia. International Journal of Cardiology. 2013; 168(4): 3439–3442. DOI: https://doi.org/10.1016/j.ijcard.2013.04.181

Langer A, Ginzburg Y. Role of hepcidin-ferroportin axis in the pathophysiology, diagnosis, and treatment of anemia of chronic inflammation. Hemodialysis International. 2017; 21: S37–S46. DOI: https://doi.org/10.1111/hdi.12543

Lakhal-Littleton S, Wolna M, Chung Y, et al. An essential cell-autonomous role for hepcidin in cardiac iron homeostasis. eLife. 2016; 5. DOI: https://doi.org/10.7554/eLife.19804